Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:59:15.768Z.
Consensus retrieved: 2026-10-06T18:02:31.629Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:59:15.768Z.
Quote observation: 2026-10-06T18:55:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f69dda8f3330533b5b8c72b5a53e0a0a6fa28851440bc7cc40968d1f378f11ab
Forward PE Ratio (N/A) = Dated Quote Price ($3.60) / Consensus Forward EPS ($-0.95)
FORWARD PE RATIO
N/A
Whitehawk Therapeutics Inc
Market Cap
$205.52M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Whitehawk Therapeutics Inc (WHWK) | $205.52M | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $204.54M | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $206.79M | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $208.05M | 21.09 |
| Exagen Inc. (XGN)vs › | $201.86M | N/A |
| Surrozen, Inc. (SRZN)vs › | $201.07M | N/A |
| Alector, Inc. (ALEC)vs › | $201.06M | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $209.74M | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.79M | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $211.56M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.60, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.95 | $-1.21 – $-0.75 | 5 | n/m |
| 2027-12-31 | $-0.89 | $-0.96 – $-0.77 | 5 | n/m |
| 2028-12-31 | $-0.81 | $-1.18 – $-0.44 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
